TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30093503

Group type: EXPERIMENTAL
Intervention: Repotrectinib (TPX-0005)
Number of subjects: 0
Study: 30093511

Group type: EXPERIMENTAL
Intervention: HbA1c ≥6.5% for diabetes diagnosis
Number of subjects: 581

Group type: COMPARATOR
Intervention: HbA1c <5.7% for normal category
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: HbA1c 5.5%-6.1% for pre-diabetes diagnosis
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: HbA1c 6.1% for type 2 diabetes diagnosis
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: HbA1c 5.5%-6.1%
Number of subjects: 581
Study: 30093518

Group type: EXPERIMENTAL
Intervention: Mild anaemia at any time during delivery
Number of subjects: 72750

Group type: EXPERIMENTAL
Intervention: Moderate/severe anaemia at any time during pregnancy
Number of subjects: 72750

Group type: EXPERIMENTAL
Intervention: Underweight at any time during pregnancy
Number of subjects: 72750

Group type: EXPERIMENTAL
Intervention: Anaemia and underweight co-existing
Number of subjects: 72750

Group type: EXPERIMENTAL
Intervention: Obesity/overweight during pregnancy
Number of subjects: 72750
Study: 30093520

Group type: EXPERIMENTAL
Intervention: PROBE questionnaire
Number of subjects: 916
Study: 30093531

Group type: EXPERIMENTAL
Intervention: Thioridazine (TDZ) 25 mg every 6 hours for 21 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Thioridazine (TDZ) 50 mg every 6 hours for 21 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Thioridazine (TDZ) 100 mg every 6 hours for 21 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Thioridazine (TDZ) with hydroxyurea
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Thioridazine (TDZ) alone
Number of subjects: 13
Study: 30093866

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with vitamin D (10 μg/day)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 122
Study: 30094070

Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic (4-cycle schedule, ≤24 doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic
Number of subjects: 24
Study: 30094213

Group type: EXPERIMENTAL
Intervention: Radial artery (RA) graft
Number of subjects: 529

Group type: COMPARATOR
Intervention: Saphenous vein graft (SVG)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Major adverse cardiac events (MACE)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Event-free cardiac survival
Number of subjects: 529
Study: 30094347

Group type: EXPERIMENTAL
Intervention: Physical activity consultation based on motivational interview technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30094730

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 45
Study: 30094930

Group type: EXPERIMENTAL
Intervention: HbSβ genotype
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30095337

Group type: EXPERIMENTAL
Intervention: Unilateral MRgFUS pallidotomy
Number of subjects: 10
Study: 30095339

Group type: EXPERIMENTAL
Intervention: GPCirA volume, presence of hydrocephalus or partial thrombosis (PT) of the aneurysm, degree of brainstem displacement (∆MT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GPCirA volume
Number of subjects: 30
Study: 30095576

Group type: EXPERIMENTAL
Intervention: Increased vitamin D dosage according to NACFF guidelines
Number of subjects: 90
Study: 30095603

Group type: EXPERIMENTAL
Intervention: XEN gel implant surgery (combined XEN+cataract surgery or standalone XEN surgery)
Number of subjects: 100
Study: 30095672

Group type: EXPERIMENTAL
Intervention: Microbial analyses including examination of alpha and beta diversity, correlational analyses of bacterial abundance, and machine learning to identify bacterial patterns.
Number of subjects: 48
Study: 30095761

Group type: EXPERIMENTAL
Intervention: Guideline-based quality indicators for postpartum hemorrhage care
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Active management of postpartum hemorrhage
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Monitoring of vital signs
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Video recordings
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Local postpartum hemorrhage protocol
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Team trainings
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: High-risk patient identification and type of hospital
Number of subjects: 398
Study: 30096071

Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (YF-17D strain)
Number of subjects: 71
Study: 30096144

Group type: EXPERIMENTAL
Intervention: Perceived Competence in Diabetes Scale (PCDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health Care Climate Questionnaire (HCCQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment Self-Regulation Questionnaire (TSRQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term complications (specifically foot-related problems)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Being female
Number of subjects: 0
Study: 30097064

Group type: EXPERIMENTAL
Intervention: Haemodiafiltration (HDF)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Conventional haemodialysis (HD)
Number of subjects: 177
Study: 30097433

Group type: EXPERIMENTAL
Intervention: Third-generation CAR T cells
Number of subjects: 15
Study: 30097477

Group type: EXPERIMENTAL
Intervention: Typical-onset FRDA
Number of subjects: 650
Study: 30097706

Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia (TEA) with levobupivacaine bolus
Number of subjects: 18

Group type: COMPARATOR
Intervention: Correction of blood pressure in 7 patients
Number of subjects: 18
Study: 30097769

Group type: EXPERIMENTAL
Intervention: Antipsychotic-naive first-episode psychosis (AN-FEP) patients
Number of subjects: 270

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Antipsychotic-naive first-episode psychosis (AN-FEP) female patients
Number of subjects: 270
Study: 30097995

Group type: COMPARATOR
Intervention: Insulin Degludec
Number of subjects: 0
Study: 30098189

Group type: EXPERIMENTAL
Intervention: mTBI participants
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normal participants
Number of subjects: 71
Study: 30098305

Group type: EXPERIMENTAL
Intervention: High intake of meat
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: High intake of vegetables
Number of subjects: 89
Study: 30098602

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion with irradiation and prolonged storage time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RBC metabolomic profiles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) for measuring intestinal oxygenation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfused RBC characteristics (irradiation and metabolism)
Number of subjects: 0
Study: 30098648

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 2 mg/24 hours (single dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 2 mg/24 hours (multiple doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch 4 mg/24 hours (multiple doses)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rotigotine transdermal patch (cold-chain PR2.1.1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (2 mg/24 hours)
Number of subjects: 24
Study: 30098677

Group type: EXPERIMENTAL
Intervention: ANCHOR Anal HSIL Health-Related Symptom Index
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Concept elicitation interviews
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cognitive interviews
Number of subjects: 45
Study: 30098707

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15mg administered twice daily for 90 days
Number of subjects: 7
Study: 30099150

Group type: EXPERIMENTAL
Intervention: Intensive mobilization under analgesic gas (equimolar mixture of oxygen and nitrous oxide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive mobilization under placebo gas (sham gas administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive mobilization under analgesic gas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive mobilization under placebo gas
Number of subjects: 0
Study: 30099268

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg) infusion over 40 min
Number of subjects: 128
Study: 30099350

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for eight weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 15
Study: 30099396

Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy (LDG) after neoadjuvant chemotherapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG) after neoadjuvant chemotherapy
Number of subjects: 96
Study: 30099397

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - intravenous infusion of 10 mL (1 g) immediately followed by three identical infusions over 8 hours (total dose of 4 g over 24 hours)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo (saline) - intravenous infusion of 40 mL over 24 hours
Number of subjects: 500
Study: 30099401

Group type: EXPERIMENTAL
Intervention: Maternity waiting homes (MWHs) intervention in 20 health facility clusters
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Standard of care for waiting mothers in 20 control clusters
Number of subjects: 2400
Study: 30099532

Group type: EXPERIMENTAL
Intervention: Baseline-dilated aortic root dimension (ARD) defined by z-score (Ao-Z > 0.80)
Number of subjects: 8573

Group type: COMPARATOR
Intervention: Non-dilated aortic root dimension (ARD)
Number of subjects: 8573
Study: 30099641

Group type: EXPERIMENTAL
Intervention: Denosumab administration
Number of subjects: 411

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 411
Study: 30099818

Group type: EXPERIMENTAL
Intervention: Sym004 6 mg/kg/wk
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sym004 9 mg/kg loading/6 mg/kg/wk
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sym004 12 mg/kg/wk
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sym004 18 mg/kg biweekly
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sym004 at the dose recommended from Part A (12 mg/kg/wk) in Part B
Number of subjects: 51
Study: 30099922

Group type: EXPERIMENTAL
Intervention: Time to start systemic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Younger age
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher ECOG performance score
Number of subjects: 0

Group type: COMPARATOR
Intervention: More than one site of metastatic disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colon site of the primary tumor
Number of subjects: 0

Group type: COMPARATOR
Intervention: No oncologic surgery to the primary tumor
Number of subjects: 0

Group type: COMPARATOR
Intervention: No concurrent bevacizumab administration
Number of subjects: 0
Study: 30100725

Group type: EXPERIMENTAL
Intervention: Teduglutide
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 30101328

Group type: EXPERIMENTAL
Intervention: Lean-marked increase group
Number of subjects: 13327

Group type: EXPERIMENTAL
Intervention: Medium-marked increase group
Number of subjects: 13327

Group type: EXPERIMENTAL
Intervention: Lean-marked increase group (adjusted for current BMI)
Number of subjects: 13327

Group type: EXPERIMENTAL
Intervention: Medium-marked increase group (adjusted for current BMI)
Number of subjects: 13327
Study: 30101330

Group type: EXPERIMENTAL
Intervention: Breastfeeding for 0-6 months
Number of subjects: 2987

Group type: EXPERIMENTAL
Intervention: Breastfeeding for 6-12 months
Number of subjects: 2987

Group type: EXPERIMENTAL
Intervention: Breastfeeding for >12 months
Number of subjects: 2987

Group type: COMPARATOR
Intervention: No breastfeeding
Number of subjects: 2987

Group type: EXPERIMENTAL
Intervention: Breastfeeding >0-6 months
Number of subjects: 2987

Group type: EXPERIMENTAL
Intervention: Breastfeeding >6-12 months
Number of subjects: 2987

Group type: EXPERIMENTAL
Intervention: Breastfeeding >12-18 months
Number of subjects: 2987

Group type: EXPERIMENTAL
Intervention: Breastfeeding >18-24 months
Number of subjects: 2987

Group type: EXPERIMENTAL
Intervention: Breastfeeding >24-36 months
Number of subjects: 2987
Study: 30101351

Group type: EXPERIMENTAL
Intervention: Low intake of riboflavin
Number of subjects: 5186

Group type: COMPARATOR
Intervention: Dietary intake of one-carbon metabolism nutrients
Number of subjects: 5186
Study: 30101387

Group type: EXPERIMENTAL
Intervention: BGJ398 daily 3 weeks on, 1 week off (dose range: 25 - 75 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BGJ398 daily 1 week on, 3 weeks off (dose range: 75 - 100 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of BGJ398 and imatinib
Number of subjects: 16
Study: 30101412

Group type: EXPERIMENTAL
Intervention: MDRO pneumonia
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Acid suppression therapy
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: History of MDRO infection
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Appropriate initial antimicrobial selection
Number of subjects: 652
Study: 30101572

Group type: EXPERIMENTAL
Intervention: PEDI-EAT-10 score > 12
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: PEDI-EAT-10 in children with airway aspiration (PAS > 5)
Number of subjects: 254

Group type: COMPARATOR
Intervention: PEDI-EAT-10 in children without aspiration (PAS < 6)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Correlation between PEDI-EAT-10 and PAS scores
Number of subjects: 254
Study: 30102205

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT) followed by gemcitabine, dexamethasone, and cisplatin (GDP)
Number of subjects: 40
Study: 30102705

Group type: EXPERIMENTAL
Intervention: High-dose rifamycins and clofazimine, specific dosage and duration not provided
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30102789

Group type: EXPERIMENTAL
Intervention: Teriparatide treatment for 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual-energy X-ray absorptiometric (DXA) measurement
Number of subjects: 0
Study: 30102967

Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg/day
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Lurasidone 80-120 mg/day
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study: 30103071

Group type: EXPERIMENTAL
Intervention: Micra transcatheter pacemaker
Number of subjects: 1817

Group type: COMPARATOR
Intervention: Micra transcatheter pacemaker (PAR)
Number of subjects: 1817
Study: 30103342

Group type: EXPERIMENTAL
Intervention: SIGNAL trial (NCT02481674)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CREST-E trial (NCT00712426)
Number of subjects: 0
Study: 30103695

Group type: EXPERIMENTAL
Intervention: Swiss Multiple Sclerosis Registry (SMSR)
Number of subjects: 1600
Study: 30103979

Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapies (ACE inhibitors, ARBs, β blockers, MRAs) at recommended doses
Number of subjects: 5276

Group type: EXPERIMENTAL
Intervention: Uptake of guideline-directed medical therapies
Number of subjects: 5276

Group type: EXPERIMENTAL
Intervention: 1-year composite outcome of all-cause death or admittance to hospital because of heart failure
Number of subjects: 5276
Study: 30104007

Group type: EXPERIMENTAL
Intervention: Veliparib and topotecan
Number of subjects: 0
Study: 30104186

Group type: EXPERIMENTAL
Intervention: Internet-delivered lifestyle intervention (yearlong digital intervention guided by health coaches)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Baseline RBANS score
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Baseline SCD-9 score
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Baseline Generalized Anxiety Disorder 7-item scale score
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Baseline Patient Health Questionnaire 9-item score
Number of subjects: 82
Study: 30104298

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients (women)
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients (men)
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients
Number of subjects: 1365
Study: 30104311

Group type: EXPERIMENTAL
Intervention: Job dissatisfaction
Number of subjects: 1906

Group type: COMPARATOR
Intervention: Mandatory accreditation attitudes
Number of subjects: 1906
Study: 30104718

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy and autologous stem cell transplantation
Number of subjects: 0
Study: 30104894

Group type: EXPERIMENTAL
Intervention: duloxetine 60 mg/day
Number of subjects: 93
Study: 30104987

Group type: EXPERIMENTAL
Intervention: Intrinsic motivation (IM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 0
Study: 30105052

Group type: EXPERIMENTAL
Intervention: Definitive Radiotherapy (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imiquimod
Number of subjects: 0
Study: 30105163

Group type: EXPERIMENTAL
Intervention: CCSVI intervention (specific details not provided)
Number of subjects: 63
Study: 30105416

Group type: EXPERIMENTAL
Intervention: Invasive ventilation
Number of subjects: 1604

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Number of subjects: 1604

Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy
Number of subjects: 1604

Group type: EXPERIMENTAL
Intervention: Standard oxygen
Number of subjects: 1604

Group type: EXPERIMENTAL
Intervention: No oxygen
Number of subjects: 1604

Group type: EXPERIMENTAL
Intervention: Severity of hypoxemia
Number of subjects: 1604

Group type: EXPERIMENTAL
Intervention: Moderate and severe hypoxemia
Number of subjects: 1604
Study: 30105602

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 2487

Group type: EXPERIMENTAL
Intervention: Loneliness
Number of subjects: 2487

Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 2487

Group type: EXPERIMENTAL
Intervention: Preoperative depression
Number of subjects: 2487
Study: 30105657

Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 2555

Group type: EXPERIMENTAL
Intervention: Micafungin (treatment for at least 1 week)
Number of subjects: 2555

Group type: EXPERIMENTAL
Intervention: Micafungin (treatment for less than 1 week)
Number of subjects: 2555

Group type: EXPERIMENTAL
Intervention: Micafungin (daily dose 50-100 mg)
Number of subjects: 2555

Group type: EXPERIMENTAL
Intervention: Micafungin (other daily doses)
Number of subjects: 2555

Group type: EXPERIMENTAL
Intervention: Micafungin (Candida-infected patients)
Number of subjects: 2555

Group type: EXPERIMENTAL
Intervention: Micafungin (Aspergillus-infected patients)
Number of subjects: 2555
Study: 30105665

Group type: EXPERIMENTAL
Intervention: Current pain intensity
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Sleep disturbances
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Drowsiness
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Breakthrough pain
Number of subjects: 606
Study: 30105951

Group type: EXPERIMENTAL
Intervention: Buparlisib, 100 mg daily
Number of subjects: 43
Study: 30106639

Group type: EXPERIMENTAL
Intervention: Serum biomarker signature derived from a case-control study using an antibody microarray platform.
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Serum biomarker signature validated in an independent case-control study in the United States.
Number of subjects: 888
Study: 30107363

Group type: EXPERIMENTAL
Intervention: Dilapan-S/Dilasoft use of <12 h (n=188)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Dilapan-S/Dilasoft use of >12 h (n=256)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Dilapan-S/Dilasoft
Number of subjects: 444
Study: 30107485

Group type: EXPERIMENTAL
Intervention: Grazoprevir-elbasvir for 12 weeks
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Grazoprevir-elbasvir for 16 weeks with ribavirin
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Risk counseling program
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 122
Study: 30107494

Group type: EXPERIMENTAL
Intervention: HCV RNA-based screening
Number of subjects: 3722
Study: 30107798

Group type: EXPERIMENTAL
Intervention: Patients with type 2 diabetes mellitus, overweight
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Patients with type 2 diabetes mellitus, obese
Number of subjects: 384

Group type: COMPARATOR
Intervention: Controls, overweight
Number of subjects: 384

Group type: COMPARATOR
Intervention: Controls, obese
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Weight gain from baseline to follow-up
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Weight loss from baseline to follow-up
Number of subjects: 384
Study: 30107811

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cells (BM MNCs)
Number of subjects: 30
Study: 30107868

Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (C1-INH) 40 IU/kg twice weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (C1-INH) 60 IU/kg twice weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C1-INH (SC)
Number of subjects: 0
Study: 30108004

Group type: EXPERIMENTAL
Intervention: Proton beam radiation therapy (PRT)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Craniospinal irradiation (CSI)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Focal PRT
Number of subjects: 155

Group type: COMPARATOR
Intervention: Older patients
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Adaptive skills
Number of subjects: 155
Study: 30108375

Group type: EXPERIMENTAL
Intervention: 4Kscore test
Number of subjects: 137
Study: 30108511

Group type: EXPERIMENTAL
Intervention: Exergaming in a moving virtual world
Number of subjects: 0
Study: 30109471

Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcome Measures (PROMIS)
Number of subjects: 23
Study: 30109728

Group type: EXPERIMENTAL
Intervention: Implementation of a facility pain management policy facilitated by a facility pain champion and training of all care workers in pain assessment and management
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Focus groups and interviews to explore feasibility and acceptability of the intervention and implementation strategies
Number of subjects: 6